BEVESPI AEROSPHERE (AstraZeneca Pty Ltd)
Product name
BEVESPI AEROSPHERE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 working days (255)
Active ingredients
glycopyrronium bromide (glycopyrrolate); formoterol (eformoterol) fumarate dihydrate
Registration type
EOI
Indication
New combination
BEVESPI AEROSPHERE (inhaler) is indicated as a long-term twice-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).